OpenAlex
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
Work
Year: 2022
Type: article
Abstract: Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms o... more
Cites: 36
Cited by: 26
Related to: 10
FWCI: 8.765
Citation percentile (by year/subfield): 88.21
Subfield: Surgery
Field: Medicine
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $5,200
Grant IDS NIH/NCI U01CA247573, SIRIC SOCRATE, MSD Avenir